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In Brief Lechman et al. show that miR-126 targets the PI3K/AKT/MTOR signaling pathway to preserve quiescence, increase selfrenewal, and promote chemotherapy resistance of acute myeloid leukemia stem cells (LSC) . Reducing the miR-126 level impairs LSC maintenance in contrast to expanding normal hematopoietic stem cells.
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INTRODUCTION
Acute myeloid leukemia (AML) is organized as an aberrant developmental hierarchy maintained by functionally distinct leukemia stem cells (LSC) (Kreso and Dick, 2014) . LSC are linked to therapy failure and disease recurrence, but they also share many biological properties with hematopoietic stem cells (HSC), including capacity for self-renewal and quiescence (Kreso and Dick, 2014) . Several self-renewal regulators have been studied in both HSC and LSC contexts including PTEN, BMI1, GFI1, TEL1, STAT5, and JUNB; except for PTEN, loss of function typically impairs self-renewal of both LSC and HSC (Yilmaz and Morrison, 2008) . LSC and HSC are both quiescent, although quiescence regulation is better understood in HSC. Several intrinsic and extrinsic signals converge upon cyclins and cyclin-dependent kinases (CDKs) that act upstream of Retinoblastoma (RB) family members to regulate early and late G 1 progression in HSC (Viatour et al., 2008) , while the G 0 state is governed by MTORC1 and CDK6 (Laurenti et al., 2015; Rodgers et al., 2014) . Quiescence and distinct G 0 exit kinetics are essential HSC properties (Trumpp et al., 2010) . Although LSC quiescence is less well defined, the known regulators appear to function similarly in LSC and HSC, with LSC quiescence often invoked as a mechanism of chemotherapy resistance (Holtz et al., 2007) . Additional studies are required to determine if differences exist in self-renewal and quiescence regulation between LSC and HSC and whether it is possible to develop therapies that eradicate LSC while sparing HSC.
Transcriptional analysis of human HSC and functionally defined LSC have defined stemness signatures that are highly prognostic for patient survival, establishing that LSC-specific properties are clinically relevant (Eppert et al., 2011; Metzeler et al., 2013) . However, little is known of how stemness programs are controlled. Several differentially expressed miRNAs were identified and found to control HSC (Hu et al., 2015; Lechman et al., 2012; Mehta et al., 2015; O'Connell et al., 2010) by coordinate repression of multiple targets (Ebert and Sharp, 2012) . In hematopoiesis, most miRNAs affect progenitor lineage commitment and mature cell function (Undi et al., 2013) , although HSC self-renewal can be governed by miR-125a/b, miR-29a, and miR-126 (Ooi et al., 2010; O'Connell et al., 2010; Guo et al., 2010; Lechman et al., 2012) . miR-126 plays a role, conserved in both human and mouse, in maintaining HSC quiescence by attenuating the cellular response to extrinsic signals via targeting multiple components of the PI3K/AKT/GSK3B signaling pathway (Lechman et al., 2012) . Thus, HSC expand without concomitant exhaustion upon miR-126 silencing.
Deregulation of miRNAs occurs in leukemia correlating with known risk categories and prognosis (Garzon et al., 2008; Li et al., 2008; Marcucci et al., 2009) . Functionally, miRNA overexpression can induce murine leukemic transformation (Han et al., 2010; O'Connell et al., 2010; Song et al., 2013) . Several LSC-associated miRNAs are functional: miR-17-92 polycistron maintained LSC in MLL models (Wong et al., 2010) , whereas antagonizing miR-196 and miR-21 reduced LSC in an experimental human MLL model (Velu et al., 2014) . Targeted miR-126 reduction in cell lines and primary AML samples reduced AML growth, although mechanisms were not reported (Dorrance et al., 2015; de Leeuw et al., 2014) . These promising studies point to the importance of further understanding the role of miRNA in governing stemness in AML. Here, we investigated the role of miR-126 in governing LSC self-renewal, quiescence, and chemotherapy resistance.
RESULTS

LSC miRNA Signature Is Prognostic for Patient Outcome
To determine whether miRNA are differentially expressed in LSC and HSC, we fractionated 16 AML patient samples and three lineage-depleted (Lin -) cord blood (CB) samples using CD34 and CD38 into four populations and subjected each to global miRNA profiling; the stem cell content of each fraction was functionally assayed by xenotransplantation ( Figures 1A and S1A ). Bioinformatic analysis of 25 LSC-enriched and 27 fractions devoid of LSC activity ( Figure S1A ) revealed a human LSC-associated miRNA signature derived from in vivo functionally validated AML patient samples ( Figure 1B ). In parallel, miRNAs enriched in HSC or committed progenitors were determined ( Figure S1B ). By comparing similar immunophenotypic AML and normal populations, several differentially expressed miRNAs were found ( Figure S1C ).
To determine if the LSC-associated miRNA signature was clinically relevant, a regression analysis was performed on 74 AML patients with normal cytogenetics (PMCC cohort, Table S1 ). An optimized LSC signature consisting of four miRNAs was identified, each with differential weights based on impact upon overall survival (OS) ( Figure 1C ). This signature was prognostic of OS in both univariate ( Figure 1D ) and multivariate analyses ( Figure 1E ) in an independent cohort. Together with prior studies showing that LSC-specific gene expression signatures are significantly prognostic (Eppert et al., 2011; Greaves, 2011) , these data establish that LSC properties influence clinical outcomes and that miRNAs play a powerful role in regulating LSC stemness.
miR-126 Bioactivity Enriches for LSC Activity
Further functional studies on AML focused on miR-126 as it is a known HSC regulator (Lechman et al., 2012) . qPCR independently confirmed that LSC-containing AML fractions generally expressed the highest miR-126 levels ( Figure S2A ). As miRNA expression does not uniformly equate with miRNA bioactivity, a miR-126 lentiviral reporter vector was used to investigate whether miR-126 is biologically active in LSC (Gentner et al., 2010) ; DNGFR levels indicate transduced cells, while EGFP levels are inversely correlated with miR-126 bioactivity (Figure S2B) . Four primary AML samples (Table S2) were transduced with the reporter, transplanted into xenografts, and after 12 weeks the engrafting population was sorted solely on the basis of miR-126 bioactivity ( Figure 2A ). Each sorted population was transplanted into secondary mice and LSC activity scored after 8 weeks, based on whether the engrafting population recapitulated the same EGFP/DNGFR flow profile as the primary recipient (a cardinal property of cancer stem cells). Despite the presence of LSC activity in multiple subpopulations with CD34 and CD38 sorting (Table S2) , miR-126 bioactivity aggregated all LSC activity into a single miR-126 high population ( Figure 2B ).
qPCR confirmed 40-fold higher mature miR-126 levels in LSCengrafting fractions compared with non-engrafting fractions for three AML samples ( Figure S2C ). LSC-containing fractions also had the highest clonogenic ( Figure S2D ) and proliferative potential ( Figure S2E ). These data indicate that miR-126 bioactivity is directly linked to LSC function and that it is possible to exploit miRNA bioactivity for prospective LSC isolation, circumventing often unreliable and heterogeneously expressed cell surface markers (Kreso and Dick, 2014) .
Clinical Relevance of miR-126 Expression
To determine if miR-126 expression alone is prognostic, the PMCC cohort (Table S1 ) was investigated, and increased miR-126 expression was found to be associated with worse OS (median OS of 28.5 months [high expression] versus not reached [low expression]; Figure 2C ), event-free survival ( Figure 2D ), and relapse-free survival ( Figure 2E ), a result in keeping with other studies (Dorrance et al., 2015; de Leeuw et al., 2014) . Since miR-126 expression is high in patients with t(8; 21) and inv(16) (Li et al., 2008) , we evaluated the prognostic value of miR-126 after excluding these patients from The Cancer Genome Atlas (TCGA) dataset. High miR-126 was associated with decreased survival in the TCGA dataset (median OS of 12.3 months [high expression] versus 18.5 months [low expression]; Figure 2F ). The prog-
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nostic significance of miR-126 further strengthens the link between AML patient outcomes, stemness properties, and the regulatory of role of miRNA (Greaves, 2011).
Development of a Functionally Relevant Human AML Model for Mechanistic Studies
How miR-126 functions throughout the AML hierarchy is difficult to investigate since functional studies in primary AML cells are technically challenging and hitherto no human AML cell lines recapitulate the hierarchical organization of primary cells. Therefore, we developed an indefinitely growing AML culture system (8227) from a relapse sample that is organized as a functional hierarchy ( Figure 3A) and LSC activity and are linked to EGFL7 expression and stem cell-specific promoter methylation patterns ( Figure S3A and E.L., unpublished data). Thus, 8227 cells are a relevant model culture system for interrogating the functional effects of miR-126 activity within the context of a leukemic hierarchy.
miR-126 Expression Induces Quiescence in Primitive AML Cells
To investigate the functional importance of miR-126 within the AML developmental hierarchy, 8227 cells were transduced with an mOrange (mO) lentivirus expressing miR-126 (126OE) or empty control vector (CTRL) ( Figure S3B ), and elevated miR-126 levels were confirmed ( Figure 3B ). Following in vitro propagation of transduced cells, the mO + CD34 + CD38 -(surrogate LSC) population was sorted and the proliferative, differentiation, and clonogenic capacity was evaluated over 28 days. By 7 days, primitive CD34 + cells increased ( Figure 3C ) and differentiated CD14 + CD15 + cells decreased ( Figure S3C ) in the 126OE group. This proportional increase in CD34 + cells correlated to transient reductions in clonogenicity of day 0 bulk cultures ( Figure S3D ); a reduction primarily confined to CD34 + CD38 + clonogenic fractions ( Figure 3D ). Bulk cultures of the 126OE group had significantly decreased (15%) bromodeoxyuridine (BrdU) incorporation at 3 hr (p = 0.002) and 16 hr (p = 0.001) compared with CTRL ( Figure 3E ). No differences in apoptosis were observed (data not shown). Cell cycle analysis of sorted 126OE populations at 7 days showed 2-fold increased proportions of quiescent (G 0 Figure 3G ), without increasing differentiation ( Figure S3G ). This effect was primarily localized to the CD34 + CD38 -compartment ( Figure 3H ). Clonogenic potential within the CD34 + CD38
À LSC-enriched compartment increased while no differences were observed in the CD34 + CD38 + progenitor-enriched compartment ( Figure 3I ). 126KD increased BrdU incorporation by 20% at 3 hr (p = 0.0024) and 16 hr (p = 0.0093) ( Figure 3J ) without affecting apoptosis (data not shown (Tables S2 and S3 ). Transduction efficiency and expression varied ( Figures S4A and S4B ), while leukemic engraftment was similar between CTRL and 126OE groups ( Figure S4C ). Although the initial transduction efficiency was $50% lower for 126OE than CTRL in six of nine AML samples, mOrange + cells within the human CD45 + graft was higher for six of nine AML samples indicating a competitive advantage for 126OE groups ( Figure S4D ). Analysis of primitive cell engraftment used both CD34 and CD117, as CD117 is associated with AML clinical outcome and correlated with miR-126 expression (de Leeuw et al., 2014; Schneider et al., 2015) . Phenotypic primitive cells were increased in 126OE groups for seven of nine samples ( Figure 4A ) with concomitant reduction of differentiated cells; four of nine samples showed a significant reduction for CD15 + cells ( Figure 4B ), and six of nine showed a trend for reduced CD14 + blasts ( Figure S4E ). 126OE caused an increase in CD15 + blasts for two samples ( Figure 4B ).
To evaluate 126OE on LSC function within the xenografts, serial transplantation with limiting dilution analysis was used to quantify LSC numbers. In three samples, LSC frequency increased in the 126OE group ( Figures 4C and S4F ). Although individual patient samples exhibited variation, overall, 126OE increased LSC self-renewal and reduced differentiation leading to LSC expansion. miR-126 Knockdown Targets LSC In Vivo 126KD was used to determine whether reducing miR-126 would impair AML engraftment or LSC function ( Figure S5A ). Total levels of human CD45 + ( Figure S5B ) or CD45 + EGFP + engraftment ( Figure S5C ) were unaffected in the 126KD group, although there was heterogeneity. By contrast, primitive CD117 + blasts were reduced in three of seven in the 126KD group, while two of seven had increased CD117 + blasts ( Figure 5A ); differentiated CD15 + CD14 + cells were increased in four of seven samples (Fig- ure 5B). The LSC frequency was reduced in two of three samples Figure S2 . Data are shown as means ± SEM of three biological replicate experiments. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S3 . Figure 6A ). The most significant pathways identified centered on PI3K/AKT/MTOR signaling, a miR-126 target pathway previously validated in primitive normal human CB cells (Lechman et al., 2012) . In addition, the protein MS data revealed a strong quiescence signature ( Figure S6A ) substantiating the in vitro cell cycle effects (Figures 3 and S3 ). Additional BrdU labeling studies with miR-126OE and miR-126KD confirmed these cell cycle effects in vivo ( Figures S6B and S6C ). The proteomic analysis was validated and confirmed by western blot of 8227 cells showing that ADAM9, PIK3R2 (p85beta), and AKT levels are reduced in 126OE groups ( Figure 6B ). Although AKT is not a predicted miR-126 target, the protein MS data show that all three AKT isoforms are reduced by 126OE (Table S4 ). In addition, many predicted and validated miR-126 targets are signaling inputs for AKT activity (Martelli et al., 2010) . To activate AKT, PDK1 is required to phosphorylate AKT on Thr 308 in the activation loop. We found that pPDK1 Ser 241 is reduced with 126OE, suggesting PDK1 activity is reduced by miR-126, further dampening AKT activation ( Figure 6C ). MTORC2 plays a critical role in AKT Ser 473 phosphorylation, a prerequisite for full AKT activation. Our proteomics analysis found that MAPKAP1 (Sin1) was downregulated by 126OE ( Figure 6A ) and since MAPKAP1 is required for MTORC2 complex formation (Yang et al., 2006) Figure S5 .
function (Birle et al., 2002) . Collectively, this integrated analysis provides strong data that miR-126 expression dampens many components of the PI3K/AKT/MTOR signaling pathway in primitive AML populations.
To characterize miR-126 targets not identified by proteomics or GSEA, all genes upregulated with 126KD and downregulated with 126OE ( Figure S6D ) were compared in collated lists of predicted miR-126 targets generated from four published prediction algorithms. Genes were ranked according to the level of perturbation by miR-126 ( Figure S6E ). Selected candidates including ADAM9, ILK, GOLPH3, CDK3, and TOM1 were confirmed as miR-126 targets using 3 0 UTR luciferase reporter assays (Figure S6F ) (Hamada et al., 2012; Oglesby et al., 2010) .
PI3K/AKT signaling ultimately converges upon cyclins and CDK that promote RB1 phosphorylation and cell cycle entry. The uncovering of CDK3 as a potential miR-126 target was intriguing as miR-126 reduces cell cycle progression and CDK3 was previously identified as a gatekeeper of G 0 -G 1 cell cycle control (Ren and Rollins, 2004) . The PI3K/AKT/MTOR pathway regulates CDKN1B (p27 kip upregulation in quiescent cells (Collado et al., 2000; Lu et al., 1999 ) and CDK3 activity is downregulated with transient p27 kip expression (Braun et al., 1998; Hsu et al., 2000) . To test the hypothesis that miR-126 modulation of PI3K/AKT/MTOR signaling influences LSC function through CDK3, functional studies were undertaken. Intracellular flow cytometry of 8227 cells showed reduced CDK3 protein levels and pRB Ser 807/811 levels upon 126OE ( Figure 6D ).
CDK3/cyclin C phosphorylation of RB1 on Ser 807/811 is required to induce cell cycle entry from a quiescent state (G 0 exit) (Ren and Rollins, 2004) (Miyata et al., 2010) To verify that 126OE functions are dependent on CDK3 downregulation, lentiviruses expressing CDK3 or the CDK3 kinase mutant (CDK3mut) were generated ( Figure S6G ) (van den Heuvel and Harlow, 1993 (Figures 6G and S6H) . Collectively, these data suggest that miR-126 restricts LSC proliferation partly through targeting CDK3.
High miR-126 Bioactivity Endows LSC with Chemotherapy Resistance
To test whether the induction of LSC quiescence by 126OE is associated with chemotherapy resistance, 126OE or CTRL transduced 8227 cells were exposed to increasing concentrations of daunorubicin. 126OE increased the survival of CD34 + cells after 72 hr of treatment compared with CTRL ( Figure 7A ), an effect not seen in non-transduced cells ( Figure S7A ). Treatment of primary AML samples (Table S5) with daunorubicin plus cytarabine resulted in enrichment of primitive CD117 + cells ( Figure S7B ) and increased miR-126 levels in four of five samples ( Figure 7B ). Thus, primitive AML cells expressing the highest miR-126 levels are also the most resistant to anti-proliferative chemotherapy.
To determine if miR-126 expression could be linked to chemotherapy resistance in a clinical setting, biobanked samples were identified from eight AML patients who failed to achieve complete remission after induction therapy. CD45 dim blasts were isolated from bone marrow at diagnosis (n = 8, day 0), day 14 (n = 4), and day 30 (n = 5) post-induction, and at day 30 after salvage chemotherapy (n = 3). In line with the in vitro findings, miR-126 expression was increased in six of eight samples (median, 3.4-fold; range, 0.3-9.4) after induction, and in two of three patients (including one in whom miR-126 expression was unchanged after induction) following salvage chemotherapy (median, 1.8-fold; range, 1.1-2.1) ( Figures 7C and S7C ). miR-126 expression was higher in relapse blasts compared with paired diagnostic samples in all four patients tested ( Figures 7D and S7D ). miR-126 expression in primitive CD45 dim CD117 + cells was increased in eight of ten patients at relapse, with >100-fold enrichment in two patients (Figures 7E and S7E) . Finally, enforced expression of CDK3 in 8227 cells rescued the 126OE effects by decreasing the proportion of CD34 + cells resistant to daunorubicin and cytarabine ( Figure 7F ). Overall, these data suggest that miR-126 confers resistance to chemotherapy, likely through the induction and maintenance of cellular quiescence by the targeting and repression of the PI3K/AKT/MTOR pathway.
DISCUSSION
Our study establishes that miRNAs play a powerful role in governing the fundamental properties that define the stemness state of human LSC including quiescence, self-renewal, and chemotherapy response. miRNAs are differentially expressed within distinct cellular subsets that make up the AML hierarchy, with a restricted set expressed in an LSC-specific manner. The miRNA LSC signature was itself highly prognostic. This clinical association, together with the miR-126 functional data, establishes that miRNAs provide a layer of post-transcriptional control critical for maintaining the stemness state in AML. Although miR-126 governs the stemness and quiescence properties of both HSC and LSC, miR-126 perturbation results in divergent selfrenewal outcomes. This discordance provides a novel avenue to therapeutically target LSC without attendant toxicity to HSC. Our study provides a mechanistic link between quiescence control and the restraint of CDK3 expression by miR-126, thereby altering RB1 phosphorylation and delaying G 0 exit in human primitive AML populations. Regulation of G 0 exit kinetics is a fundamental HSC property, distinct from downstream progenitors, that is essential for maintaining HSC pool integrity (Laurenti et al., 2015; Nygren et al., 2006) . CDK3 is poorly studied since all inbred mice carry a nonsense mutation in CDK3 (Ye et al., 2001) . In quiescent human fibroblasts, CDK3 can complex with CCNC (cyclin C) and phosphorylate Rb1 (on residues S 807 and S
811
) to directly initiate the cell cycle; when CDK3 levels are reduced, a 12-hr lag in G 0 exit kinetics is induced but not a permanent block (Ren and Rollins, 2004) . In murine LT-HSC, CCNC levels are highest during G 0 exit (Passegué et al., 2005) and CCNC knockdown in human HSC increased quiescence, promoted HSPC expansion, and increased repopulation capacity (Miyata et al., 2010) . In leukemia, CCNC deletion highly correlates with relapse (van Delft et al., 2011) . Thus, it is likely that the miR-126/CDK3 regulatory axis also governs G 0 exit kinetics in LSC, thereby providing new therapeutic opportunities for targeting quiescence control of LSC. . Graph below represents three independent intracellular flow experiments for each condition where the mean fluorescence intensity was compared. Mean ± SEM; *p=<0.05 and ****p=<0.0001. (E) Graph depicting enhanced expansion of bulk 8227 cultures after enforced expression of CDK3 and mutCDK3. Fold expansion is normalized to mutCDK3 control culture day 7 after transduction. Data shown are the mean ± SEM of three replicate experiments; *p=<0.05. Figure S6 and Table S3 . The miR-126 expression levels in daunorubicin/AraC-treated and control AML blasts were determined by qPCR. Results were normalized to RNU48 and are shown as the mean ± SD of four replicates; ***p < 0.001, ****p < 0.0001. (C) qPCR was performed on CD45 dim sorted blasts from patient samples at diagnosis (n = 8, day 0) and at day 14 (n = 4) and day 30 (n = 5) after initiation of induction chemotherapy, as well as on day 30 after (unsuccessful) salvage chemotherapy (n = 3). Data shown are pooled from individual patients (see Figure S7C ) and are shown as means ± SEM of combined individual patient samples. *p < 0.05. (D and E) qPCR results of the relative levels of miR-126 in CD45 dim (D, four AML patients, see Figure S7D ) and CD45 dim CD117 + (E, ten AML patients, see Figure S7E ). AML blasts in paired diagnosis and relapse patient samples shown as the mean ± SEM of all patients combined; *p < 0.05. (F) 8227 cells transduced with mutCDK3 and CDK3 lentiviruses were plated into a 96-well plate and treated with increasing doses of daunorubicin for 48 hr. Cells were stained for CD34 and live cells were identified by viability dye exclusion by flow cytometry. Results are shown as the mean ± SEM of four biological replicates; *p < 0.05 and **p < 0.01. See also Figure S7 and Table S4. being rarely mutated and likely driven by upstream activation (Fransecky et al., 2015) . Although inhibitors of AKT, MTOR, and PI3K are in clinical development, they have mostly failed for AML (Fransecky et al., 2015) . While failure is attributed to feedback loops, our study provides an explanation that is embedded in the hierarchical organization of AML. PI3K/AKT/ MTOR signaling is restricted to cycling leukemic progenitors; by contrast, quiescent LSC, a reservoir of leukemic relapse, have lower signaling and would then be spared following inhibitor treatment. In support of this prediction, AKT inhibition increased the fraction of G 0 breast cancer cells, linking low AKT signaling to a G 0 -like state (Dey-Guha et al., 2011) . In AKT knockout mice, HSC persisted in an enhanced G 0 quiescent state, while AKT activation results in HSC hyper-proliferation and exhaustion (Juntilla et al., 2010; Kharas et al., 2010) . Collectively, these reports suggest that the state of AKT activity plays a key role in governing quiescence of normal HSC and our data extend this concept to leukemia by showing that this pathway is tightly controlled at multiple points by miRNAs in order to maintain the human LSC state. Although cell cycle regulation by miR-126 is similar between HSC and LSC, the functional consequence is the opposite: reduced miR-126 levels expand HSC in vivo, but impair LSC maintenance (see the model in Figure 8 ). With the exception of PTEN, known regulators of self-renewal have similar functions in normal and leukemic contexts (Yilmaz and Morrison, 2008) . PTEN is rarely mutated in AML, yet experimental deletion results in HSC loss and LSC expansion, supporting our data on functional HSC-LSC divergence. Concordant with our findings of low PI3K/AKT/MTOR signaling in dormant LSC, rapamycin treatment only eliminates LSC during the early phases of leukemic initiation in PTEN mouse models when LSC are proliferating, but not when leukemia is fully developed and when some LSC are predicted to re-enter quiescence (Yilmaz and Morrison, 2008) .
While targeting stemness represents a promising clinical direction, finding a selective therapeutic window might be challenging due to the shared determinants of stemness between HSC and LSC, and the likelihood of causing excessive toxicity (Kreso and Dick, 2014) . The distinct function of miR-126 in HSC and LSC provides an opportunity to clinically target LSC while sparing HSC. Moreover, inhibiting miR-126 might overcome LSC chemoresistance through cycle activation and increasing sensitivity to anti-proliferative drugs. Although targeting miRNA in vivo is still , which phosphorylates AKT, and MAPKAP1, which is required for MTORC2 formation and full activation of AKT. Significantly diminished levels of AKT activity preferentially retain LSC in a quiescent state by increasing p27 levels, together with miR-126 targeted reduction of CDK3. Under high miR-126 levels, LSC that do enter the cycle are biased toward a self-renewal division. Reduction of LSC miR-126 levels through currently unspecified developmental cues (or lentiviral spongemediated) de-represses the expression and activity of multiple AKT signaling inputs. LSC now preferentially cycle and are biased toward differentiation divisions.
inefficient (Brown and Naldini, 2009) , LNA miRNA decoy technology is effective clinically in hepatitis C (Janssen et al., 2013) . Alternatively, targeting the LSC-specific pathways identified by miR-126 might also be an effective strategy.
EXPERIMENTAL PROCEDURES
Patient-Derived Xenografts NOD/Lt-scid/IL2Rɣnull (NSG) mice were bred at the University Health Network/Princess Margaret Cancer Center. Animal experiments were performed in accordance with national and institutional guidelines approved by the Canadian Counsel on Animal Care and approved by the University Health Network Animal Care Committee. Mouse xenografts were performed as described previously (Lechman et al., 2012) . Briefly, NSG mice were sublethally irradiated (225 cGy) 1 day prior to injection. AML patient samples were thawed and plated in X-VIVO/20% BIT (Stem Cell Technologies) supplemented with Flt3-L (50 ng/ml), IL-6 (10 ng/ml), stem cell factor (50 ng/ml), thrombopoietin (125 ng/ml), IL-3 (10 ng/ml), granulocyte colony-stimulating factor (10 ng/ml) for 18 hr (Blair et al., 1998) . Cells were transduced in 24-well culture plates at a multiplicity of infection of 30 with sensor lentivectors or for enforced expression and knockdown of miR-126. Transduced AML cells (5 3 10 5 -1 3 10 6 ) were injected with 25 ml of PBS into the right femur of each recipient mouse. After 10-12 weeks, the mice were euthanized and bone marrow cells were flushed with 2 ml of PBS, 2% fetal calf serum, and 50 ml of cells were stained for surface markers.
Patient Samples and Treatment Protocols
Between 2003 and 2010, peripheral blood and bone marrow samples were collected from subjects with AML after obtaining informed consent according to procedures approved by the Research Ethics Board of the University Health Network (REB# 01-0573-C). Mononuclear cells were isolated and stored as previously described (Eppert et al., 2011) . Cytogenetics were analyzed according to the revised MRC prognostic classification system (Grimwade et al., 2010) . NPM1 and FLT3-ITD mutations were assessed as previously described (How et al., 2012) . The 74 patient samples used to optimize the miRNA prognostic signature (PMCC cohort) were diagnostic samples from individuals with de novo AML and normal cytogenetics. Although patients were not treated uniformly, all initially received induction chemotherapy followed by two cycles of consolidation in those who achieved complete remission (CR). First-line induction regimens included 3 + 7 (n = 69), NOVE-HIDAC (n = 1), and four patients were enrolled in clinical trials employing a 3 + 7 backbone with gemtuzumab ozogamicin (n = 2) or tipifarnib (n = 2). Treatment protocols were as previously described (Brandwein et al., 2008; Brandwein et al., 2009; How et al., 2012; Petersdorf et al., 2013) . Allogeneic stem cell transplant (allo-SCT) was performed for high-risk patients in CR1 (n = 7), as well as for patients who achieved a second remission after relapse (n = 12) if they had an available donor, were younger than 70 years, lacked significant comorbidities, and had good performance status. Bio-informatic and clinical information for a second cohort of 187 de novo AML patients was obtained from TCGA and has been previously described (Cancer Genome Atlas Research Network, 2013 (A) Quantitative PCR (qPCR) for mature miR-126 levels in flow sorted AML sub-fractions (see scheme depicted in Figure 1A) . Data was normalized to RNU48 control levels. Results are shown as mean ± SEM of n=3 technical replicates.
(B) Schematic of the bi-directional miR-126 biosensor vector. The vector expresses truncated NGFR in one direction (which marks all transduced cells) and eGFP in the other direction. miR-126 binding sites are cloned downstream of eGFP. The more miR-126 a cell expresses, the less eGFP protein that is translated, leading to lower levels of eGFP fluorescence.
(C) (A) Schematic of the EGFL7/miR-126 locus. Promoter methylation was determined by CD34/CD38 sorting of 8227 subpopulations. Methylated DNA immunoprecipitation (MeDIP) combined with tiling array hybridization. High methylation of the internal miR-126 promoter suggests that miR-126 expression is regulated from the EGFL7 promotor 2 site, which is progressively methylated with increasing differentiation of the 8227 cells. This differentiation is correlated with changes in cellular function as measured by in vitro culture initiation, in vivo leukemia initiation, colony forming capacity, and proliferation. Furthermore, miR-126 expression by array (normalized log2 transformed levels) and EGFL7 expression levels from array (normalized log2 transformed levels) are highest in the LSC enriched fraction and are progressively reduced with increasing differentiation. miR-126 bioactivity, as measured by the miR-126 biosensor vector, is highest in the LSC fraction and decreases with differentiation. (A) Comparison of the proteomics data against published quiescent/proliferative signatures. For the proliferative gene sets, Mann Whitney non-parametric analysis was used to test the significance of the overlap between the published proliferative signatures and the proteomic gene set that was up-regulated in miR-126OE. For the quiescent gene sets, Mann Whitney nonparametric analysis was used to look for significance of the overlap between the quiescent signature and proteomic gene set that was down-regulated in miR-126OE. Grey dots represent all the different proteomics ranks t values. Red dots represent proteins found in the gene set of interest with a t-value greater than 0. Blue dots represent proteins found in the gene set of interest with a t value less than 0. The p value indicated below each gene set is the most significant Wilcox p value from the two scenarios tested, "greater" (red), "less" (blue). The yellow dotted line shows the mean of the proteomic ranks t-values. (C) miR-126 levels in 8 individual AML patients who failed to achieve complete remission (CR) after anthracycline/cytarabin induction chemotherapy. qPCR was performed on CD45 dim sorted blasts from 8 patient samples at diagnosis (n=8, day 0) and, at day 14 (n=4) and day 30 (n=5) after initiation of induction chemotherapy, as well as on day 30 after (unsuccessful) salvage chemotherapy (n=3).
(D-E) Levels of miR-126 in individual paired diagnosis/relapse AML patient samples. AML patient samples were thawed and sorted for CD45 dim Clinical parameters of the AML patient bone marrow samples used for in vitro stromal chemotherapy assay (AML 19 to AML 23), AML patient cohort that failed to achieve complete remission (AML 24 to AML 31), and paired diagnosis/relapse AML patient samples (AML32 to AML 41). (Hu and Smyth, 2009 ).
Nanostring miRNA data generation and processing
The expression of 30 miRNAs from 74 acute myeloid leukemia (AML) samples from Princess Margaret Cancer Centre (PMCC) were measured and normalized using the NanoString platform (Geiss et al., 2008) . For the TCGA cohort, miRNA-Seq RPM (i.e., reads per million) normalized profiles generated using the Illumina Genome Analyzer, which captured the expression of ~492 miRNAs, were downloaded from the TCGA data portal (Cancer Genome Atlas Research Network, 2013) . The maximum linear expression of 29 mature miRNAs that were common to both datasets was analyzed in this study. All miRNA expression values were increased by one plus a small normally distributed random value to produce non-zero expression profiles. These profiles were then log 2 transformed and filtered for miRNAs with high variance (i.e., values outside of the 20 th to 80 th percentile range). Finally, ComBat normalization was applied to reduce the cross-platform differences (i.e., batch effects) between the 2 datasets (Johnson et al., 2007 ) (Fei et al., 2013) (Rudy and Valafar, 2011) (Sirinukunwattana et al., 2013) . All data analysis was done in R 2.15.2.
Building prognostic miRNA signatures
The glmnet 1.9-3 R package was configured for L1 regularized Cox regression, enabled with leave one out cross validation. This statistical learning tool was then applied to the PMCC dataset to select a minimal weighted combination of miRNA expression that best explained patient survival time. This training phase resulted in a 4-miRNA signature that was tested for prognostic value in the TCGA dataset. Per-patient risk scores were computed using dot products between the expression of signature miRNAs (i.e., c i ) and their corresponding regression coefficients (i.e., weights w i ) as follows: (w 1  c 1 ) + (w 2  c 2 ) + (w 3  c 3 ) + … etc. The resulting continuous scores were further discretized based on the 50th percentile (i.e., median) split, where patients with scores above the split were considered to be at high risk (else low risk) as previously described (Eppert et al., 2011) .
miRNA signature performance
In survival analysis, overall survival (OS) was defined as the time from AML diagnosis until death from any cause, event-free survival (EFS) was defined as the time from AML diagnosis until induction failure, relapse, or death from any cause, and relapse-free survival (RFS) defined as the time from the date of first complete remission (CR1) until relapse or death, regardless of cause (Cheson et al., 2003) . The survival 2.37-4 package in R (Borgan, 2001 ) was used to assess the prognostic value of the miRNA signature scores computed for each patient in the TCGA dataset. Survival differences between patients with low-and high-signature scores were assessed using uni-and multi-variate Cox proportional hazards (CPH) and Kaplan-Meier models. (2) the ability of the signature scores to significantly dichotomize low-from high-risk patients in univariate survival models (p<0.05, log rank test). in all replicates of any one condition were eliminated, leaving 15812 probes for analysis.
Illumina Microarray
Gene set enrichment analysis
Gene set enrichment analysis was performed using g:Profiler software with the options significant only, ordered query on 2564 genes selected based both on a positive log fold change (logFC) in 8227 126/KD and a negative logFC in 8227 126/OE versus Control samples (Reimand et al., 2011) . Gene-sets with a size equal or greater than 500 were removed. Results were visualized using Cytoscape 2.8.1 (Smoot et al., 2011) and an enrichment map (version 1.2 of Enrichment Map software (Merico et al., 2010) was generated using enriched gene-sets with a p-value <0.05 and overlap coefficient set of 0.5.
Mass Spectrometry Sample Preparation
One to two weeks post viral transduction, 8227 cells with miR-126 overexpression (126/OE) and control vector (CTRL) were counted and washed twice with ice-cold PBS. 100,000 cells for each experimental condition, in biological triplicate, were subjected to sample preparation similar to (Kulak et al., 2014) . Cells were lysed using 50 l of lysis buffer (consisting of 6 M Guanidinium 
Mass Spectrometry Acquisition
For each SCX fraction, peptides were loaded onto a 50cm C18 reverse-phase analytical column (Thermo EasySpray ES803) using 100% Buffer A (0.1% Formic acid in water) at 750bar, using the Thermo EasyLC 1000 HPLC system in a single-column setup and the column oven operating at 45°C. Peptides were eluted over a 140 minute gradient ranging from 5 to 48% of or maximum injection time of 50ms, fragmented with a normalized collision energy of 30 and the resulting MS2 spectra were obtained in the ion trap. Dynamic exclusion was set to 60 seconds, and ions with a charge state <2, >7 or unknown were excluded.
MS performance was verified for consistency by running complex cell lysate quality control standards, and chromatography was monitored to check for reproducibility. Each sample was run in technical duplicate and biological triplicate, and the reproducibility of the analyses is depicted in aLahIn44) (Hermjakob and Apweiler, 2006) .
Label-free Quantitative Proteomics Analysis
The raw files were analyzed using MaxQuant version 1.5.2.8 (Cox and Mann, 2008) 
Proteomics
MaxQuant LFQ (Cox and Mann, 2008) intensities were used as a measure of protein expression in 8227 126OE and control samples. The entire protein expression set consisting of 3 biological replicates for each treatment group and corresponding technical replicates (total of 12 samples) was quantile normalized in R (R version 3.1.1) using the normalizer package (version 1.0). The normalized protein expression was further filtered to contain only proteins that had at least two measurements in either treatment or control.
Difference in protein expression between the groups was assessed using a moderated t-test available in the bioconductor limma package (version 3.20.9). P-values were further corrected to control for multiple hypothesis testing using the Benjamini-Hochberg procedure. 638 proteins had significant differential expression with nominal p-value <0.05, of those 451 were upregulated (t>0) and 187 were downregulated (t<0). Proteins and their corresponding t-statistic were used to create a rank file to be used in pathway analysis described below.
Pathway Analysis on the proteomics data
Gene Set Enrichment Analysis (Subramanian et al., 2005) was performed using the protein expression ordered from largest to smallest t statistics with parameters set to 1000 gene-set permutations and gene-sets size between 5 and 500. 
miRNA labeling
Target preparation was done according to (Lu et al., 2005) . Briefly, two synthetic pre-labeled control nucleotides (5' -pCAGUCAGUCAGUCAGUCAGUCAG-3', and 5'-pGACCUCCAUGUAACGUACAA-3', Dharmacon) were spiked at 3fmoles per g of total RNA to control for target preparation control. Small RNA's were recovered for 1-10 g total RNA by PAGE purification and adaptor ligated sequentially on the 3' end and the 5' end using T4 RNA ligase (Amersham Biosciences). After reverse transcription using adaptor specific primers, products were PCR amplified for 18 cycles for 10 g starting total RNA using 3' -primer 5'-TACTGGAATTCGCGGTTA-3' and 5' primer-biotin-CAAACGAATTCCTCACTAA-3'(IDT). PCR products were precipitated and dissolved in 66 l TE buffer (10 mM Tris-HCL pH 8.0, 1 mM EDTA) containing two biotinylated post-labelling control oligonucleotides (100 fmoles of FVR506, 25 fmoles PTG20210).
Bead based detection
As described in (Lu et al., 2005) , miRNA capture probes were conjugated to carboxylated xMAP beads (Luminex Corportion) in a 96-well plate. Samples were hybridized in a 96 well plate, with 2 mock PCR samples in each plate as a background control. Hybridization was carried out overnight. Beads were spun down, resuspended in 1x TMAC containing 10 g/mL -1 streptavividin-phycoerythrin (Molecular probes) before data acquisition of a Luminex 1001S machine. Median fluorescence intensity values were measured.
miRNA array computational analysis
Profiling data was scaled to the post-labelling controls and then the pre-labelling controls, in order to normalize readings from different probe/bead sets for the same sample and to normalize for the labelling efficiency, respectively. Data were threshholded at 32 and log 2 transformed.
The LSC miRNA signature was generated using a Smyth's moderated t-test with BenjaminiHochberg multiple testing correction to compare fractions positive for LSCs versus those without LSCs.
Luciferase Reporter assay
Luciferase assay (Switchgear Genomics) was performed according to the manufacturers' protocol. Briefly, 293T cells were seeded to 40% confluency in 100 l total volume in 96 well white TC plates (NUNC). The next day, equal volumes of mixture 1 (GoClone reporters; 30 ng/l, miR-126 mimic or non-targeting mimic; 100 nM, and serum free media) was combined with mixture 2, (Dharmafect Duo/serum-free media) and incubated at room temperature RT for 20 minutes. After incubation, 4 volumes of pre-warmed serum-free media were added and mixed. 100 l of the mixture was added to each well containing 293T cells and incubated overnight. Reconstituted luciferase substrate (100 l) was added to each well, incubated at RT for 30 minutes and read for 2 seconds on a spectraMAX luminometer. Knockdown was determined by calculating the luciferase signal ratio for each reporter construct for miR-126 over the non-targeting control miRNA. GoClone control reporters used were GAPDH-3'UTR, ACTB-3'UTR, EMPTY-3'UTR, R01, and gene specific reporters were ADAM9-UTR, ILK-UTR, GOLPH3-3'UTR, CDK3-3'UTR and TOM1-3'UTR.
AML Stromal Chemotherapy Assay
Low passage MS5 stromal cells were seeded into 0.1% gelatin coated 96 well tissue culture plates and cultured for 48 hours in H5100 media (SCF; 100 ng/ml, TPO; 50 ng/ml. IL-7; 20 ng/ml, IL-3; 10 ng/ml, IL-6; 20 ng/ml, FLT3L; 10 ng/ml, G-CSF; 20 ng/ml, GM-CSF; 20 ng/ml) with 1% penicillin/streptomycin. After two days, primary patient AML cells (depleted for human T cells; 1x10 5 /well) were plated onto MS5 stroma and cultured overnight. After 24 hours, cells were treated with vehicle or with Daunorubicin/AraC (1:1 ratio; 50 ng/mL Daunorubicin and 500 ng/mL Ara-C) for 72 hours. Cells were recovered and evaluated for live cell content and immuno-phenotype by flow cytometry. Total RNA was recovered for qPCR detection of miR-126 levels.
Intracellular and Phosphoflow
Cultured 8227 cells were washed twice with 1x PBS and pelleted to eliminate culture medium.
After washing, cells were stained for CD34 and CD38 cell surface antigens for 20 minutes at RT.
Cells were washed and pelleted. Cells were immediately fixed with paraformaldehyde (final concentration: 1.6%) for 10 minutes at room temperature. Cells were then centrifuged, washed once with PBS 1% BSA to remove residual PFA and permeabilized with ice-cold Perm buffer III (BD Phosflow for 30 min at 4°C followed by 2 washes in order to remove traces of methanol). 
Western blot analysis
8227 cells were cultured as described and transduced with viral particles at a multiplicity of infection (MOI) of 30 for at least 16 hours. Cells were allowed to expand for 14 days and then flow sorted for mO + cells. Total cellular proteins were extracted with RIPA buffer (20 mM TrisHCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100) supplemented with protease and phosphatase inhibitors: 1 mM PMSF, 10 mM NaF, 1 mM Na 3 VO 4 , CompleteMini™ and PhosStop ™ (Roche). Samples were resuspended in the lysis solution and incubated at 4°C for 30 minutes. Cell lysates were cleared by centrifugation at 10,000×g for 10 minutes at 4°C, and the supernatants were collected and assayed for protein concentration using Lowry assay based method (DC, BioRad). 40-50 micrograms of proteins were run on SDS-PAGE under reducing conditions. For immunoblotting, proteins were transferred to PVDF membranes, incubated with the specific antibody (anti-ADAM9 Cell Signaling #2099 1:1000, and ant-pan AKT Cell Signaling # 4685 1:500, anti-PIK3R2 Cell Signaling #4257 1:1000, and GAPDH 1:10,000, Sigma) followed by peroxidase-conjugated secondary antibodies. Bands were visualized on Kodak BioMax film.
Lentiviral constructs, cell culture and colony formation
Lentiviral vector platforms for ectopic miRNA expression, stable knockdown and live cell miRreporting were described previously (Gentner et al., 2010) . Third generation lentiviral vector particles pseudotyped with VSV-G were generated as described (Guenechea et al., 2000) . 
Ki67 and Hoechst flow cytometry
Cells were stained for surface markers, washed and fixed using BD Cytofix buffer, washed and permeabilized with BD Perm 2 (BD), washed and stained with PE-or FITC-or PerCP-Cy5.5 conjugated Ki67 antibody (BD) and finally resuspended in BD Cytofix buffer with Hoechst at 1 µg/mL. The cells were then analyzed on a BD LSRII machine with a UV laser.
Quantitative PCR
miR-126 expression was analyzed as described (Lechman et al., 2012) . Briefly, small RNAs were extracted using Trizol (Life Technologies) and miRNA expression levels were determined by the Applied Biosystems Taqman® microRNA Assay system. Reactions were carried out in triplicate in an ABI Prism 7900HT (Applied Biosystems, Foster City, CA). miRNA expression was normalized to RNU48.
Statistical analysis
Unless otherwise indicated, mean + SEM values are reported in the graphs. For pairwise comparisons, a Mann-Whitney non-parametric test was used unless otherwise indicated.
